LEANNE GALVAN: Open Payments
NPI 1730648759 · OMAHA, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,934 in 110 payments from 31 companies in 2025. Trend: 2023 $1,451 · 2024 $1,620 · 2025 $1,934
Food & beverage: $1,889Education: $45
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 26 | $379 |
| Amgen Inc. | 11 | $242 |
| Lilly USA, LLC | 7 | $147 |
| AstraZeneca Pharmaceuticals LP | 8 | $143 |
| PFIZER INC. | 11 | $139 |
| Novo Nordisk Inc | 5 | $81 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $78 |
| HARMONY BIOSCIENCES LLC | 4 | $70 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $64 |
| Abbott Laboratories | 2 | $48 |
Products named: VRAYLAR, REPATHA, UBRELVY, NURTEC ODT, XIFAXAN, QULIPTA, WAKIX, OTEZLA.
Industry payments across NE — which companies pay providers there.
